In the early trials, the vaccine showed efficacy in protection against influenza A, influenza B and COVID-19. Data also showed that the combination vaccine has a similar safety profile to Pfizer’s normal COVID-19 shot.
“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world,” said Annaliesa Anderson, PhD, senior vice president and the head of vaccine research and development at Pfizer.
The experimental shot will enter a phase 3 trial in a matter of months.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
